advantage 100 mg/ml šķīdums pilināšanai uz ādas
elanco animal health gmbh, vācija - imidakloprīdu - šķīdums pilināšanai uz ādas - 100 mg/ml - kaķi
credelio plus
elanco gmbh - lotilaner, milbemycin oxime - endectocide - suņi - for use in dogs with, or at risk from, mixed infestations/infections of ticks, fleas, gastrointestinal nematodes, heartworm and/or lungworm.
rilonacept regeneron (previously arcalyst)
regeneron uk limited - rilonacepts - cryopyrin saistītie periodiskie sindromi - imūnsupresanti - rilonacept regeneron tiek norādīts cryopyrin saistīto periodisku sindromi (caps) ārstēšanai ar smagi simptomi, ieskaitot ģimenisko aukstā auto iekaisuma sindroms (fcas) un muckle wells sindroms (mws) pieaugušajiem un bērniem vecumā no 12 gadiem un vecāki.
roferon-a 3 miljoni starptautisko vienību (sv) šķīdums injekcijām pilnšļircē
roche latvija, sia, latvija - interferons, alfa-2a - Šķīdums injekcijām pilnšļircē - 3 miljoni sv/0,5 ml
roferon-a 3 miljoni starptautisko vienību (sv)/0,5 ml šķīdums injekcijām pilnšļircē
roche bulgaria eood, bulgaria - interferons, alfa-2a - Šķīdums injekcijām pilnšļircē - 3 miljoni sv/0,5 ml
roferon-a 3 miljoni starptautisko vienību (sv) šķīdums injekcijām pilnšļircē
roche products limited, united kingdom - interferons, alfa-2a - Šķīdums injekcijām pilnšļircē - 3 miljoni sv/0,5 ml
libtayo
regeneron ireland designated activity company (dac) - cemiplimab - karcinoma, švamšā šūna - antineoplastiski līdzekļi - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.
alpheon
biopartners gmbh - recombinant human interferon alfa-2a - c hepatīts, hronisks - imunitātes stimulatori, - adult patients with histologically proven chronic hepatitis c who are positive for hepatitis c virus (hcv) antibodies or hcv rna and have elevated serum alanine aminotransferase (alt) without liver decompensation. the efficacy of interferon alfa-2a in the treatment of hepatitis c is enhanced when combined with ribavirin. alpheon should be given alone mainly in case of intolerance or contra-indication to ribavirin.